SI3345613T1 - Sestavek za uporabo pri zdravljenju raka ali z angiogenezo povezane bolezni, ki obsega fuzijski protein iz tumor-penetrirajočega peptida in sredstva anti-VEGF - Google Patents
Sestavek za uporabo pri zdravljenju raka ali z angiogenezo povezane bolezni, ki obsega fuzijski protein iz tumor-penetrirajočega peptida in sredstva anti-VEGFInfo
- Publication number
- SI3345613T1 SI3345613T1 SI201631730T SI201631730T SI3345613T1 SI 3345613 T1 SI3345613 T1 SI 3345613T1 SI 201631730 T SI201631730 T SI 201631730T SI 201631730 T SI201631730 T SI 201631730T SI 3345613 T1 SI3345613 T1 SI 3345613T1
- Authority
- SI
- Slovenia
- Prior art keywords
- angiogenesis
- tumor
- composition
- fusion protein
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 230000033115 angiogenesis Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150123878 | 2015-09-01 | ||
| EP16842324.2A EP3345613B1 (en) | 2015-09-01 | 2016-09-01 | Composition for use in treating cancer or an angiogenesis-related disease comprising a fusion protein of a tumor-penetrating peptide and an anti-vegf agent |
| PCT/KR2016/009801 WO2017039358A1 (ko) | 2015-09-01 | 2016-09-01 | 종양 투과성 펩타이드와 향-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3345613T1 true SI3345613T1 (sl) | 2023-10-30 |
Family
ID=58188859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201631730T SI3345613T1 (sl) | 2015-09-01 | 2016-09-01 | Sestavek za uporabo pri zdravljenju raka ali z angiogenezo povezane bolezni, ki obsega fuzijski protein iz tumor-penetrirajočega peptida in sredstva anti-VEGF |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10919947B2 (sl) |
| EP (1) | EP3345613B1 (sl) |
| JP (1) | JP6893928B2 (sl) |
| KR (1) | KR102128966B1 (sl) |
| CN (1) | CN108348575B (sl) |
| AU (1) | AU2016317882B2 (sl) |
| BR (1) | BR112018004078A2 (sl) |
| CA (1) | CA2996937C (sl) |
| DK (1) | DK3345613T5 (sl) |
| ES (1) | ES2951260T3 (sl) |
| FI (1) | FI3345613T3 (sl) |
| MX (1) | MX395266B (sl) |
| RU (1) | RU2727238C2 (sl) |
| SI (1) | SI3345613T1 (sl) |
| WO (1) | WO2017039358A1 (sl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR101948238B1 (ko) | 2016-08-19 | 2019-02-14 | (주)케어젠 | 미녹시딜과 펩타이드의 결합체 |
| JP7362113B2 (ja) * | 2017-06-28 | 2023-10-17 | エルジー ハウスホールド アンド ヘルスケア リミテッド | 皮膚透過促進用ペプチドが結合された融合タンパク質を含む皮膚改善用化粧料組成物 |
| BR112020001045A2 (pt) * | 2017-07-18 | 2020-09-08 | In3Bio Ltd. | proteínas sintéticas e usos terapêuticos das mesmas |
| KR20190028343A (ko) * | 2017-09-08 | 2019-03-18 | 아주대학교산학협력단 | 뉴로필린 1 (Neuropilin 1, NRP1)에 특이적으로 결합하는 펩타이드를 포함하는 조절 T 세포의 활성을 억제하기 위한 조성물 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| EP3863657A4 (en) * | 2018-10-12 | 2022-07-20 | Trican Biotechnology Co., Ltd | BIFUNCTIONAL FUSION PROTEINS AND USES THEREOF |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN112641928A (zh) * | 2019-10-11 | 2021-04-13 | 田中纯美 | 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途 |
| CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
| CN112522322A (zh) * | 2020-12-24 | 2021-03-19 | 深圳市人民医院 | 一种nrp1配体的修饰技术 |
| CN114028541A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | Gdf2在制备改善肿瘤异常血管的药物中的用途 |
| WO2023134787A2 (zh) * | 2022-01-14 | 2023-07-20 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途 |
| KR102459219B1 (ko) * | 2022-03-31 | 2022-10-26 | 주식회사 셀아이콘랩 | 신규한 피부투과성 펩타이드, 이를 포함하는 피부 및 점막 조성물과 이의 용도 |
| AU2024252640A1 (en) | 2023-04-07 | 2025-10-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| RU2008106230A (ru) * | 2005-07-19 | 2009-08-27 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) | Средства проникновения через гематоэнцефалический барьер и внутрь клеток раковой опухоли мозга и способы их использования |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| BRPI0812398A2 (pt) | 2007-06-06 | 2019-09-24 | Domantis Ltd | domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão |
| CN102869384B (zh) * | 2009-06-22 | 2016-01-13 | 伯纳姆医学研究所 | 使用带有c-端元件的肽和蛋白质的方法和组合物 |
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| CA2860226C (en) * | 2011-12-22 | 2022-10-18 | Randolph S. Watnick | Saposin-a derived peptides and uses thereof |
| US9116159B2 (en) * | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
| WO2014189303A1 (ko) * | 2013-05-23 | 2014-11-27 | 아주대학교산학협력단 | 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질 |
| KR101551306B1 (ko) * | 2015-03-23 | 2015-09-09 | 아주대학교산학협력단 | 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도 |
-
2016
- 2016-09-01 WO PCT/KR2016/009801 patent/WO2017039358A1/ko not_active Ceased
- 2016-09-01 CN CN201680060604.2A patent/CN108348575B/zh not_active Expired - Fee Related
- 2016-09-01 SI SI201631730T patent/SI3345613T1/sl unknown
- 2016-09-01 AU AU2016317882A patent/AU2016317882B2/en not_active Ceased
- 2016-09-01 DK DK16842324.2T patent/DK3345613T5/da active
- 2016-09-01 CA CA2996937A patent/CA2996937C/en active Active
- 2016-09-01 EP EP16842324.2A patent/EP3345613B1/en active Active
- 2016-09-01 KR KR1020160112699A patent/KR102128966B1/ko active Active
- 2016-09-01 FI FIEP16842324.2T patent/FI3345613T3/fi active
- 2016-09-01 RU RU2018111390A patent/RU2727238C2/ru active
- 2016-09-01 JP JP2018530461A patent/JP6893928B2/ja active Active
- 2016-09-01 MX MX2018002524A patent/MX395266B/es unknown
- 2016-09-01 ES ES16842324T patent/ES2951260T3/es active Active
- 2016-09-01 BR BR112018004078-9A patent/BR112018004078A2/pt active Search and Examination
-
2018
- 2018-03-01 US US15/909,086 patent/US10919947B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6893928B2 (ja) | 2021-06-23 |
| EP3345613B1 (en) | 2023-05-10 |
| CN108348575B (zh) | 2022-06-14 |
| ES2951260T3 (es) | 2023-10-19 |
| JP2018531989A (ja) | 2018-11-01 |
| US20180237484A1 (en) | 2018-08-23 |
| CA2996937C (en) | 2024-02-06 |
| BR112018004078A2 (pt) | 2018-12-11 |
| CN108348575A (zh) | 2018-07-31 |
| CA2996937A1 (en) | 2017-03-09 |
| AU2016317882B2 (en) | 2021-01-28 |
| FI3345613T3 (fi) | 2023-07-28 |
| RU2018111390A (ru) | 2019-10-04 |
| RU2727238C2 (ru) | 2020-07-21 |
| US10919947B2 (en) | 2021-02-16 |
| KR102128966B1 (ko) | 2020-07-01 |
| RU2018111390A3 (sl) | 2020-01-31 |
| AU2016317882A1 (en) | 2018-04-19 |
| DK3345613T5 (da) | 2024-09-30 |
| EP3345613A1 (en) | 2018-07-11 |
| EP3345613A4 (en) | 2019-08-14 |
| WO2017039358A1 (ko) | 2017-03-09 |
| KR20170027312A (ko) | 2017-03-09 |
| MX395266B (es) | 2025-03-25 |
| MX2018002524A (es) | 2018-11-09 |
| DK3345613T3 (da) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3345613T1 (sl) | Sestavek za uporabo pri zdravljenju raka ali z angiogenezo povezane bolezni, ki obsega fuzijski protein iz tumor-penetrirajočega peptida in sredstva anti-VEGF | |
| ZA201802003B (en) | Dual function proteins and pharmaceutical composition comprising same | |
| PL3892631T3 (pl) | Białko fuzyjne do zastosowania w leczeniu choroby hvg | |
| IL287291A (en) | A protein that binds to rgma and its use | |
| SG10202001485UA (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
| IL269741A (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| SI3565828T1 (sl) | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo | |
| IL256515A (en) | Therapeutic peptides and methods of use thereof | |
| EP3238736A4 (en) | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same | |
| IL249131A0 (en) | A method for reducing the immunogenicity of protein and peptide | |
| IL274008A (en) | Anti-MSLN antibody and a pharmaceutical preparation containing it for the treatment of cancer | |
| PT3387019T (pt) | Proteínas de fusão de imunoglobulina de relaxina e métodos de uso | |
| SG11201610947UA (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| HUE059500T2 (hu) | Aminosavakat tartalmazó készítmények elhízás kezelésében történõ alkalmazásra | |
| PT3283528T (pt) | Anticorpo humano anti-vegfr2 para terapia antiangiogénica e direcionada ao cancro | |
| DK3472190T3 (da) | Fiibronectin-bindende peptider til anvendelse i tumor- og fibrosediagnosticering og -behandling | |
| EP3139955A4 (en) | Fusion proteins for treating cancer and related methods | |
| EP3506924A4 (en) | nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS | |
| PT3545965T (pt) | Novos péptidos e combinações de péptidos para uso na imunoterapia contra o carcinoma hepatocelular (chc) e outros cancros | |
| IL249610A0 (en) | Chimeric proteins for cancer treatment | |
| PT3438118T (pt) | Derivado de peptídeo e utilização deste | |
| PL3262069T3 (pl) | Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu | |
| EP3139944A4 (en) | Use of peptide for treating angiogenesis-related diseases | |
| PL3072529T3 (pl) | Kompozycja zawierająca wemurafenib i HPMC-AS | |
| SG11202101945PA (en) | Peptide therapeutics for the treatment of cancer and uses thereof |